Menu
Chairs: Stefan Anker, Germany, & Fausto Pinto, Portugal
10:00-10:20 – “Prometheus” basic science key note lecture:
Targeting the ubiquitin proteasome system to fight muscle atrophy: update 2022
Volker Adams, Germany
10:25-10:45 – “Hippocrates” clinical science key note lecture:
From sarcopenia to frailty
John Morley, USA
10:50-10:58 – JCSM & SCWD lecture
Stephan von Haehling, Germany
Chairs: Paola Costelli, Italy, & Kamyar Kalantar-Zadeh, USA
11:15-11:24 – MOTS-c: a new player in aging-related loss of muscle mass and function
Changhan David Lee, USA
11:26-11:35 – Metabolic and molecular consequences of sarcopenia in alcoholic liver disease
Srinivasan Dasarathy, USA
11:37-11:46 – Bone and muscle crosstalk: Biological and clinical implications
Gustavo Duque, Australia
11:48-11:57 – Results of the SPRINTT trial
Francesco Landi, Italy
Chairs: Stephan Herzig, Germany, & Robert Mak, USA
11:15-11:24 – Immune-sympathetic neuron communication guides adipose tissue browning in cancer-associated cachexia
Martina Schweiger, Austria
11:26-11:35 – Angiocrine signals promote adipose tissue wasting in cancer cachexia
Andreas Fischer, Germany
11:37-11:46 – Brown adipose tissue activation is not related to hypermetabolism in emphysematous COPD patients
Annemie Schols, The Netherlands
11:48-11:57 – MRI-determined psoas muscle fat infiltration correlates with severity of weight loss during cancer cachexia
Dimitrios Karampinos, Germany
Chairs: Kamyar Kalantar-Zadeh, USA, & Stephan von Haehling, Germany
13:00-13:12 – Appetite is key in geriatric syndromes: a pre-release of SCWD International guidelines on anorexia of aging
Ivan Aprahamian, Brazil
13:15-13:27 – Development of the cachexia consensus in Asia
Hidenori Arai, Japan
13:30-13:42 – Recent guidelines on cancer cachexia: ESPEN, ESMO and ASCO
Alessandro Laviano, Italy
Chairs: Fabio Penna, Italy, & Vera Mazurak, Canada
13:00-13:09 – Doxorubicin-induced skeletal muscle atrophy, underlying molecular pathways and potential protective effects of exercise: Evidence from pre-clinical and clinical data
Anouk Hiensch, The Netherlands
13:11-13:20 – Exercise and Nutrition-based Rehabilitation programme (EneRgy) in people with cancer
Barry Laird, UK
13:22-13:31 – Resistance training during chemotherapy for non-metastatic colon cancer: The FORCE study: Effects on body composition and physical function
Bette Caan, USA
13:33-13:42 – Effects of exercise in patients after curative treatment for esophageal cancer: body composition and adequacy of energy and protein intake (the PERFECT study)
Anne May, The Netherlands
Poster session 1.1
Cancer cachexia I (posters 4-14 to 4-23 + 5-04)
Chairs: Andrea Bonetto, Andreas Fischer
Poster session 1.2
Diagnosis of cachexia and sarcopenia I (posters 1-25 to 1-34)
Chairs: Wolfram Doehner, Peter Martin
Poster session 1.3
Cachexia – mechanisms I (posters 3-09 to 3-18)
Chairs: Alessio Molfino, Marco Sandri
Poster session 1.4
Therapeutic development I (posters 6-01 to 6-10)
Chairs: Andrew Judge, Jochen Springer
Chairs: Denis Guttridge, USA, & Julia von Maltzahn, Germany
13:50-13:55 – Body composition assessment by artificial intelligence from routine CT scans in colorectal cancer, introducing BodySegAI (1-04)
Dena Helene Alavi, Norway
13:55-14:00 – Towards artificial intelligence: point-of-care musculoskeletal ultrasound correlates with body composition, muscle strength and physical performance in children with acute lymphoblastic leukemia (1-12)
Emma J. Verwaaijen, The Netherlands
14:00-14:05 – Two years of aging – initial results on changes in muscle composition in the UK Biobank imaging study (1-26)
Dahlqvist Leinhard, Sweden
14:05-14:10 – Long-haul COVID-19 is related to lower pectoralis muscle mass at hospital admission for treatment of acute infection (2-07)
Marilia Seelaender, Brazil
14:10-14:15 – Chronic activation of ALK5/TGFbRI signaling in adult mouse skeletal muscle induces severe muscle wasting with concomitant impaired mitochondrial integrity (2-12)
Laetitia Mazelin, France
14:15-14:20 – The effect of severe burns on skeletal muscle protein balance in female rats 10 and 40 days post-burn (2-14)
Dorien Dombrecht, Belgium
14:20-14:25 – Sex differences in skeletal muscle-ageing trajectory: same processes, but with different magnitudes (2-19)
Jelle de Jong, The Netherlands
14:25-14:30 – Mechanosignaling through YAP/TAZ drives fibroadipogenic progenitors activation and promotes paraspinal muscle fibrosis in degenerative scoliosis (2-21)
Abdukahar Kiram, China
Chairs: Andrew Judge, USA, & Gustavo Nader, USA
Activation of Akt-mTORC1 signaling reverts cancer-dependent muscle wasting
Bert Blaauw, Italy
New insights into the role of GCN2-eIF2alpha signaling in the regulation of autophagy
Anne-Catherine Maurin, France
Interventions for improving mitochondrial function to counteract cancer and chemotherapy-induced cachexia
Fabio Penna, Italy
Fighting muscle loss: lessons from hibernation in brown bear
Etienne Lefai, France
Chairs: Maurizio Muscaritoli, Italy, & Anne May, The Netherlands
Measuring muscle in oncology research and interventions
Elizabeth Cespedes Feliciano, USA
Artificial Intelligence approaches to improve speed, dimensionality and entry into clinical workflows
Faisal Beg, Canada
Surrogate markers of muscle mass and quality
M. Cristina Gonzalez, Brazil
A mechanistic perspective of specialized nutrition for muscle health
Philip Atherton, UK
Poster session 2.1
Muscle wasting & sarcopenia – mechanisms I (posters 2-20 to 2-29)
Chairs: Achim Krüger, Changhan David Lee
Poster session 2.2
Cancer cachexia II (posters 4-24 to 4-36)
Chairs: Andrea Bonetto, Andreas Fischer
Poster session 2.3
Physical activity & training (posters 7-01 to 7-09)
Chairs: Anne May, Ashley Smuder
Poster session 2.4
Diagnosis of cachexia and sarcopenia II (posters 1-01 to 1-12 + 1-26)
Chairs: Wolfram Doehner, Peter Martin
Rapid Fire Abstracts Session 2
Chairs: Laure Bindels, Belgium, & Gustavo Duque, Australia
15:35-15:40 – The relationship between cachexia and inflammatory biomarkers in patients with cancer; initial findings from the REVOLUTION cachexia characterisation study (4-04)
Robert Paval, UK
15:40-15:45 – Identifying cancer patients with cachexia at scale by leveraging self-supervised natural language processing and predictive models on unstructured data in patients’ electronic health records (4-08)
Richard Skipworth; Barry Laird, UK
15:45-15:50 – Examining the negative impact of weight loss and cachexia in Chimeric Antigen Receptor (CAR) T-cell therapy (4-09)
Brittany Cucchiaro, UK
15:50-15:55 – Evaluation of weight gain and overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy (4-11)
Eric Roeland, USA
15:55-16:00 – Assessment of muscle and lean mass in colon cancer patients on chemotherapy: correlations of d3-creatine, dual energy x-ray absorptiometry and computed tomography (4-16)
Elisabeth M. Cespedes Feliciano, USA
16:00-16:05 – NAD+ repletion with niacin counteracts cancer cachexia (4-19)
Marc Beltrà Bach, Italy
16:05-16:10 – Respiratory Muscle Pathology in Esophageal Adenocarcinoma Patients (4-31)
Miles Cameron, USA
16:10-16:15 – Ketogenic diet slows down tumor growth but induces primary adrenal insufficiency that accelerates onset of cachexia in C26 and KPC murine models (3-05)
Miriam Ferrer Gonzalez, USA
16:15-16:20 – Colon cancer treatment with FOLFIRI exacerbates muscle fiber atrophy and induces a catabolic transcriptional program in skeletal muscle (3-08)
Vickie Baracos, Canada
Chairs: Andreas Fischer, Germany, & Yi-Ping Li, USA
Mechanisms of ammonia induced sarcopenia – a common mediator in multiple diseases
Srinivasan Dasarathy, USA
Amino acid perturbations in hyperammonemia
Milan Holecek, Czech Republic
Multiomics based approaches to identify novel cellular and tissue responses
Nicole Welch, USA
The significance of myosteatosis in surgical cancer patients
Steven Olde Damink, The Netherlands
Chair: Paula Ravasco, Portugal
What determines/Which parameters determine optimal protein metabolism in the old?
Dominique Dardevet, France
Manipulating the microbiome to counteract frailty
Patrizia Brigidi, Italy
Nutrition and anorexia of ageing
Reshma Merchant, Singapore
Combining power food and fasting in cachexia: no go or wise go?
Florian Strasser, Switzerland
Chairs: Andrea Bonetto, USA, & M. Cristina Gonzalez, Brazil
Hepatic and intestinal microbial disturbances as therapeutic targets in cancer cachexia
Laure Bindels, Belgium
A cachexia score based on liver alterations predicts prognosis of gastrointestinal cancer patients
Achim Krüger, Germany
Inflammation and impairment of hepatic metabolism and function in cachectic cancer patients
Marilia Seelaender, Brazil
Transcriptional reprogramming of hepatocyte function in cancer cachexia
Sören Fisker Schmidt, Denmark
Chairs: Joe Chakkalakal, USA, & Nicholas Greene, USA
Muscle stem cells in age and disease
Julia von Maltzahn, Germany
Neurofibromatosis type 1 associated myopathy is due to metabolic reprogramming of muscle stem cells in a mouse model
Sigmar Stricker, Germany
Fibro-adipogenic progenitors coordinate muscle regeneration
Georgios Kotsaris, Germany
Muscle stem cells drive post-sepsis skeletal muscle recovery and regeneration
Jason Doles, USA
Chairs: Frank Misselwitz, Germany, & Gustavo Nader, USA
Abnormal liver-bone-muscle axis in cancer cachexia
Andrea Bonetto, USA
Impact of exercise and chemotherapy on the respiratory neuromuscular system
Ashley Smuder, USA
Cancer-induced muscle and bone deficits
Hanna Taipaleenmäki, Germany
A prospective study of hand-grip strength to predict mortality in patients with cancer with and without cachexia
Markus Anker, Germany
Poster session 3.1
Muscle wasting and sarcopenia – mechanisms II (posters 2-01 to 2-09)
Chairs: Denis Guttridge, Milan Holecek
Poster session 3.2
Nutrition & appetite (posters 5-01 to 5-09)
Chairs: Philip Atherton, Adrian Slee
Poster session 3.3
Diagnosis of cachexia and sarcopenia III (posters 1-14 to 1-24)
Chairs: Dimitrios Karampinos, Martina Schweiger
Chairs: Anouk Hiensch, The Netherlands, & Richard Skipworth, UK
10:50-10:55 – Muscle Wasting in Early-stage Cancer is Associated with Disorganized Extracellular Matrix Distinct from Fibrosis (4-25)
Erin E Talbert, USA
10:55-11:00 – Study of the histological and inflammatory rearrangements of the subcutaneous adipose tissue among gastrointestinal cancer patients with cachexia (4-32)
Alessio Molfino, Italy
11:00-11:05 – Targeted dietary intervention attenuates experimental lung cancer cachexia (5-04)
Wouter van de Worp, The Netherlands
11:05-11:10 – Leptin, Adiponectin, and Mortality Risk in a Prospective Hemodialysis Cohort (5-07)
Connie Rhee, USA
11:10-11:15 – Deletion of FNDC5/Irisin protects against cancer induced cachexia syndrome (6-09)
Fabrizio Pin, USA
11:15-11:20 – Effects of Bioarginine C supplementation on functional parameters in adults with Long Covid: a randomised clinical trial (6-15)
Matteo Tosato, Italy
11:20-11:25 – Metoprolol attenuates stimulated lipolysis in adipose tissue from cachectic patients with pancreatic cancer (6-08)
Lenka Rossmeislova, Czech Republic
Chairs: Jochen Springer, Germany, & Marilia Seelaender, Brazil
Sex-dependent response of adipose tissue and lipid metabolism in cancer cachexia
Vera Mazurak, Canada
Tumor microenvironment evolution and its relevance to cachexia
Mariam Jamal-Hanjani, UK
Sex variation in cachexia
Silvia Busquets, Spain
Tumor-specific ribosomal deficits in muscle wasting
Gustavo Nader, USA
Chairs: Gustavo Duque, Australia, & Barry Laird, UK
Integrated evaluation of body composition in the oncology setting: paradigm change
David da Silva Dias, Portugal
Nutrition options in 2022: What is on the market?
Paula Ravasco, Portugal
Nutrition in ambulatory cytotoxic treatment: New data on the role of the clinical pharmacist
Leila Costa, Portugal
Head and neck cancer and cachexia – a high risk cancer and higher risk treatments
Maartje van Beers, The Netherlands
Circulating GDF15 and its relationship with cachexia in non-small cell lung cancer
Mariam Jamal-Hanjani, UK
GDF-15 is a key regulator of cancer cachexia and beyond
Bei Zhang, USA
Questions & Answers
Supported by an educational grant from Pfizer
Chairs: Denis Guttridge, USA, & Maria Rohm, Germany
Reprogramming of liver and neutrophil metabolism in cancer cachexia
Tobias Janowitz, USA
Tumor-derived cachexia mediators and biomarkers
Mauricio Berriel Diaz, Germany
Tumor-derived extracellular vesicles
Paola Costelli, Italy
KLF10: a novel mediator of cancer-associated skeletal muscle wasting
Jason Doles, USA
Chairs: Vickie Baracos, Canada, & Ashley Smuder, USA
Exercise and tumor control: expanding the field of exercise oncology to cancer progression and cachexia
Lee Jones, USA
Cardiac wasting in cancer
Alessia Lena, Germany
A review of the evidence for multi-modal interventions in cachexia management
Joanne Reid, UK
ACTAs for cancer cachexia
Andrew Coats, Australia
Poster session 4.1
Therapeutic development II (posters 6-11 to 6-19)
Chairs: Yi-Ping Li, Anne-Catherine Maurin
Poster session 4.2
Cachexia – mechanisms II (posters 3-02 to 3-08)
Chairs: Silvia Busquets, Marco Sandri
Poster session 4.3
Cancer cachexia III (posters 4-01 to 4-12 + 4-31)
Chairs: Sören Fisker Schmidt, Fabio Penna
Poster session 4.4
Muscle wasting & sarcopenia – mechanisms III (posters 2-11 to 2-19)
Chairs: Rodney Infante, Sigmar Stricker
Chairs: Paola Costelli, Italy, & Tobias Janowitz, USA
MyomiRNA, systemic and local inflammation and muscle wasting
Maurizio Muscaritoli, Italy
The transcriptional repressor FoxP1 in cancer-induced skeletal muscle wasting and weakness
Sarah Judge, USA
Beyond good and evil: Discovering novel anabolic targets to overcome cancer related-muscle wasting
Marcelo Pereira, UK
Skeletal muscle mitochondrial dysfunction and lipid accumulation in breast cancer
Emidio Pistilli, USA
Chairs: Teresa Zimmers, USA, Bette Caan, USA, & Andrew Coats, Australia
Muscle mass criterion for cachexia: measuring muscle mass in clinical trials
Vickie Baracos, Canada
Selecting populations for clinical trials
Eric Roeland, USA
Endpoints for cancer cachexia clinical trials
Stefan Anker, Germany
Use of biomarkers to assess treatment effect in cancer cachexia
Jose Garcia, USA
Regulatory perspective on Cancer Cachexia Trials
Giuseppe Rosano, UK
Chairs: Marco Sandri, Italy, & Denis Guttridge, USA
T cells and cachexia
Laura Antonio-Herrera, Austria
Aging exacerbates neuromuscular junction disruption after injury that stimulates inflammation
Joe Chakkalakal, USA
Macrophages and muscle regeneration
Emanuele Berardi, Belgium
Endothelial dysfunction in cachexia
Young-Mee Kim, USA
Judges: Hidenori Arai, Japan, Vickie Baracos, Canada, Bette Caan, USA, Jose Garcia, USA, Paula Ravasco, Portugal, & Jochen Springer, Germany
16:35-16:42 – MicroRNA-22 as a potential diagnostic tool in males with sarcopenic heart failure: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) (1-29)
Mirela Vatic, Germany
16:44-16:51 – STumor metabolic activity is associated with myosteatosis and reduced survival in patients with non-small cell lung cancer (4-15)
Yan Sun, The Netherlands
16:53-17:00 – OPA1 overexpression may protect against cancer-induced muscle wasting (4-22)
Stavroula Tsitkanou, USA
17:02-17:09 – Intramuscular lipid alterations in human pancreatic cancer cachexia (4-34)
Min Deng, The Netherlands
17:11-17:18 – Leucine-rich diet improves cachexia index and alters tumour thermogenic capacity in Lewis Lung tumour-bearing aged mice (5-03)
Natalia Angelo da Silva Miyaguti, Brazil
Chair: Puneeth Iyengar, USA
Host factors: sexual dimorphism in murine models of cancer cachexia
Nicholas Greene, USA
Host factors: aging and host genotype in cancer cachexia
Maria Rohm, Germany
Tumor factors: tumor molecular and cellular heterogeneity mediates cancer cachexia phenotype
Teresa Zimmers, USA
Identification of molecules that contribute to NSCLC cancer cachexia
Rodney Infante, USA
Chairs: Philip Atherton, UK, & Stephan von Haehling, Germany
Impact of protein intake on CKD cachexia and sarcopenia
Kam Kalantar-Zadeh, USA
Physical activity and nutrition in CKD
Angela Wang, Hong Kong
Inflammation and adipose tissue browning in CKD cachexia
Robert Mak, USA
Activin signaling and GDF-15 in CKD cachexia
Connie Rhee, USA
Chair: Hidenori Arai, Japan & Annemie Schols, The Netherlands
The role of adipose tissue in Covid-19 cytokine storm: learning from cachexia
Marilia Seelaender, Brazil
Nutrition: a matter of life or death
Alessandro Laviano, Italy
Body composition and muscle quality in Covid-19 patients
Martine Sealy, The Netherlands
Frailty and rehabilitation in Covid-19 patients
Francesco Landi, Italy
Chairs: Joanne Reid, UK, & Martine Sealy, The Netherlands
Evolution and outcomes from a multi-disciplinary cachexia clinic
Peter Martin, Australia
Clarifying the role of palliative rehabilitation in cachexia management
Cathy Payne, Belgium
The importance of exercise and nutrition in an integrated response to cachexia management
Adrian Slee, UK
Patient experience of a multi-professional cachexia clinic
Vanessa Vaughan, Australia
Chair: Teresa Zimmers, USA, & Steven Olde Damink, The Netherlands
MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer
Andrew R. Judge, USA
Activation of p38β MAPK in skeletal muscle correlates with weight loss in cancer patients
Yi-Ping Li, USA
Association between growth differentiation factor-15 (GDF-15) serum levels, anorexia and low muscle mass among cancer patients
Alessio Molfino, Italy
Adipose depot gene expression and intelectin-1 in the metabolic response to cancer and cachexia
Richard J. E. Skipworth, UK
Chair: Francesco Landi, Italy
Speakers: Waly Dioh, France, & Cendrine Tourette, France
Supported by an educational grant from Biophytis
Chairs: Stefan Anker, Germany, Andrew Coats, & Jose Garcia, USA
From ROMANA to SCALA program: The journey of Anamorelin – the ghrelin receptor agonist – towards treating the malignancy associated weight loss and anorexia in adult patients with non-small cell lung cancer (NSCLC)
Daniela Domnica Rotaru, Italy
Use of chirally pure S-enantiomers in the treatment of cancer cachexia: Clinical Development of S-pindolol benzoate in cancer cachexia in patients with advanced Non-Small Cell Lung and Colo-Rectal Cancer
Frank Misselwitz, Germany
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status – insights from EMPEROR-Preserved trial
Andrew Coats, Australia
Chairs: Maurizio Muscaritoli, Italy, & Jochen Springer, Germany
GDF15 neutralization as a transformative therapeutic approach
Bei Zhang, Pfizer, USA
Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15
Danna Breen, USA
MC4R antagonism for appetite and body weight regulation – from human genetics to aged rat model
Zhidan Wu, USA
Beyond cachexia: the inhibition of antitumoral immune responses by cachexia-inducing tumor-derived factor GDF-15
Christine Schuberth-Wagner, Germany
Chairs: Vickie Baracos, Canada & Andrew Coats, Australia
Basic Science
Maria Rohm, Germany
Clinical & Biomarkers
Stephan von Haehling, Germany
Sarcopenia
Maurizio Muscaritoli, Italy
Treatment
Frank Misselwitz, Germany
Poster Award
Young Investigator Award
Farewell
Copyright © 2009 – 2022 Society on Sarcopenia, Cachexia and Wasting Disorders. All Rights Reserved. Data Privacy